ClinicalTrials.gg
RecruitingNCT07307066REALVENTUpdated Jul 1, 2026

Real-Time Algorithm-Driven Ventilation Feedback to Improve Lung-Protective Ventilation in Patients With ARDS (REALVENT-study)

An interventional study of REal-time Algorithm-driven Ventilation feedback to improve lung-protective ventilation in critically and Standard ICU care in ARDS (Acute Respiratory Distress Syndrome), VILI (Ventilator-induced Lung Injury) and Respiratory Failure, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Acute Lung Injury with a site in China — 20 open to participants now, 20 under way, 1 of them phase 3. Acute Lung Injury · China.

Planned enrollment
5th of 31
208 · median 60
Started
2025
with 4 others
No phase
20 of 59
6 open now
Primary completion
2026-12
later than 8 of 19 live
Registered
49th of 59
by date
Lead sponsor
7 of 59
Peking Union Medical College Hospital

Among the 59 studies in Acute Lung Injury with a site in China, this one is the 5th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2025, is one of 20 with no phase, reaches primary completion later than 8 of the 19 other live ones, and was the 49th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

20 of the 59 studies in Acute Lung Injury with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acute Lung Injury with a site in China, or all of them as a file.
02

Study summary

The REALVENT trial is designed to evaluate whether a real-time, algorithm-driven ventilation feedback strategy can improve lung-protective ventilation (LPV) achievement rates in critically ill patients receiving invasive mechanical ventilation. This multicentre randomised controlled trial will compare real-time respiratory waveform monitoring with automated feedback against standard ICU care. The primary endpoint is the LPV achievement rate over the first 72 hours.

Read the detailed description

Mechanical ventilation is essential in modern intensive care but may cause ventilator-induced lung injury (VILI) when delivered with excessive tidal volume, airway pressure, or mechanical power, or in the presence of unrecognised patient-ventilator asynchrony. Despite guideline recommendations to limit tidal volume, plateau pressure, and driving pressure, real-world adherence to lung-protective ventilation (LPV) remains suboptimal, and clinicians often rely on intermittent, manual review of ventilator settings and waveforms.

The REALVENT trial tests a cloud-based respiratory dynamics monitoring and feedback system that continuously acquires high-frequency ventilator waveforms (pressure, flow, volume) and automatically computes key LPV metrics, including tidal volume indexed to predicted body weight, driving pressure, plateau pressure, mechanical power, and patient-ventilator asynchrony events. For patients in the intervention arm, the platform provides three layers of feedback over the first 72 hours after randomisation: (1) real-time alerts when LPV thresholds are exceeded; (2) 4-hour window indicator checks to capture sustained deviations; and (3) standardised 24-hour summary reports with recommendations for ventilator adjustment. These reports are reviewed by bedside clinicians and a central monitoring team, but all treatment decisions remain at the discretion of the local ICU team.

The control group receives usual care with standard bedside ventilator monitoring but without structured feedback from the platform. All other aspects of care, including fluid management, sedation, prone positioning, neuromuscular blockade, and adjunct respiratory monitoring (e.g., esophageal manometry or EIT), are left to clinician judgement and recorded.

The primary hypothesis is that algorithm-driven feedback will increase the proportion of time during the first 72 hours that all four LPV targets are simultaneously achieved compared with standard care. Secondary hypotheses are that improved LPV adherence will translate into more ventilator-free days, fewer ventilator-associated complications, lower inflammatory biomarker levels, and acceptable clinician workload and usability ratings.

03

Conditions studied

  • ARDS (Acute Respiratory Distress Syndrome)
  • VILI (Ventilator-induced Lung Injury)
  • Respiratory Failure
  • Critical Illness
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years
  • Receiving invasive mechanical ventilation via endotracheal intubation at the time of screening
  • Initiation of invasive mechanical ventilation within the past 24 hours
  • PaO₂/FiO₂ ≤ 200 mmHg on PEEP ≥ 8 cmH₂O or, if arterial blood gas is unavailable: SpO₂/FiO₂ ≤ 235 with SpO₂ ≤ 97%
  • Chest imaging (chest X-ray or CT) showing bilateral pulmonary infiltrates not fully explained by pleural effusions, lobar collapse, or pulmonary nodules
  • Respiratory failure not fully explained by cardiac failure or fluid overload
  • Expected to require invasive mechanical ventilation for ≥ 72 hours after enrollment

Exclusion criteria

Exclusion Criteria:

  • Receipt of extracorporeal membrane oxygenation (ECMO) or high-frequency oscillatory ventilation at screening
  • Brain death or anticipated withdrawal of life-sustaining treatment within 72 hours
  • Pregnancy
  • Known neuromuscular disease affecting spontaneous respiratory effort
  • Prisoners or individuals unable to provide or surrogate consent
  • Simultaneous enrollment in another interventional ICU study
  • Lack of digital infrastructure for real-time ventilator waveform acquisition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    REal-time Algorithm-driven Ventilation feedback to improve lung-protective ventilation in critically

    Patients in the intervention arm will receive real-time ventilator waveform monitoring through the respiratory dynamics monitoring and feedback RemoteVentilate ViewTM system. The system continuously collects high-frequency waveform data (flow, pressure, volume) directly from the ventilator interface and analyses the following metrics: Tidal volume (VT) indexed to predicted body weight, Driving pressure (ΔP), Plateau pressure (Pplat), and Mechanical power (MP). Patient-ventilator asynchrony (PVA) events will be also collected in the system, including double triggering, ineffective efforts, reverse triggering, and flow starvation, ect

    Device: REal-time Algorithm-driven Ventilation feedback to improve lung-protective ventilation in critically

  • Active comparator
    Standard ICU care

    The control group will receive standard ICU care, including routine monitoring of ventilator parameters such as tidal volume, plateau pressure, and oxygenation status. No structured feedback or external ventilation reports will be provided. This reflects the prevailing standard of care in Chinese ICUs and is thus an appropriate comparator for assessing the added value of a real-time respiratory feedback platform.

    Other: Standard ICU care

Interventions

  • DeviceREal-time Algorithm-driven Ventilation feedback to improve lung-protective ventilation in critically

    Patients in the intervention arm will receive real-time ventilator waveform monitoring through the respiratory dynamics monitoring and feedback RemoteVentilate ViewTM system. The system continuously collects high-frequency waveform data (flow, pressure, volume) directly from the ventilator interface and analyses the following metrics: Tidal volume (VT) indexed to predicted body weight, Driving pressure (ΔP), Plateau pressure (Pplat), and Mechanical power (MP). Patient-ventilator asynchrony (PVA) events will be also collected in the system, including double triggering, ineffective efforts, reverse triggering, and flow starvation, etc..

  • OtherStandard ICU care

    The control group will receive standard ICU care, including routine monitoring of ventilator parameters such as tidal volume, plateau pressure, and oxygenation status. No structured feedback or external ventilation reports will be provided. This reflects the prevailing standard of care in Chinese ICUs and is thus an appropriate comparator for assessing the added value of a real-time respiratory feedback platform.

06

What researchers measure

Primary outcomes

  1. The daily lung-protective ventilation achievement rate

    The primary outcome is the daily lung-protective ventilation achievement rate over the first 72 hours following randomisation. Lung-protective ventilation is defined as simultaneous fulfilment of all of the following four criteria: Tidal volume (VT) \< 8 mL/kg predicted body weight (PBW); Driving pressure (ΔP) \< 15 cmH₂O; Plateau pressure (Pplat) \< 30 cmH₂O; Mechanical power (MP) \< 17 J/min. The daily achievement rate is calculated as the number of hours within each 24-hour period where all four targets are met, divided by 24, and expressed as a percentage. The mean of the three daily rates over the 72-hour period will be used as the primary outcome. This outcome reflects both physiological safety and clinician behaviour, and was selected based on its strong mechanistic link with ventilator-induced lung injury and previous observational data on variability in adherence

    Time frame: Over the first 72 hours following randomisation

Secondary outcomes

  1. Ventilator-free days at day 28 (VFD-28)

    defined as the number of days alive and free from invasive mechanical ventilation between randomisation and day 28, with patients who die before day 28 considered as having 0 VFDs;

    Time frame: Day 28 after trial enrollment

  2. ICU length of stay

    total number of days from ICU admission to ICU discharge;

    Time frame: 28 days after ICU admission

  3. Serum concentration of interleukin-1 beta (IL-1β)

    Serum IL-1β concentration measured using standardized immunoassays.

    Time frame: Baseline (within 24hours) and 72 hours after trial enrollment

  4. Serum concentration of interleukin-6 (IL-6)

    Serum IL-6 concentration measured using standardized immunoassays.

    Time frame: Baseline (within 24hours) and 72 hours after trial enrollment

  5. Serum concentration of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1)

    Serum sTREM-1 concentration measured using standardized immunoassays.

    Time frame: Baseline (within 24hours) and 72 hours after trial enrollment

  6. Incidence of ventilator-associated pneumonia (VAP)

    based on CDC criteria, adjudicated by two independent reviewers;

    Time frame: 72 hours after trial enrollment

  7. Incidence of barotrauma

    including pneumothorax, pneumomediastinum, or subcutaneous emphysema confirmed radiographically

    Time frame: 72 hours after trial enrollment

  8. ECMO initiation rate

    proportion of patients who require extracorporeal support during the index ICU stay;

    Time frame: 72 hours after trial enrollment

  9. Mortality at day 28

    all-cause mortality;

    Time frame: Day 28 after trial enrollment

  10. Modified NASA Task Load Index (NASA-TLX) score (0-100)

    Six-domain modified NASA-TLX; each domain rated 0-20; performance reverse-scored; mean transformed to 0-100; higher scores indicate greater perceived workload.

    Time frame: 72 hours after trial enrollment

  11. Clinician-reported usability score (mean of 5-item, 5-point Likert scale; range 1-5)

    Five items rated 1-5; mean score reported; higher scores indicate better perceived usability.

    Time frame: 72 hours after trial enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Liu S, Zhao Z, Chen X, Chi Y, Yuan S, Cai F, Song Z, Ma Y, He H, Su L, Long Y. Evaluation of health care providers' ability to identify patient-ventilator triggering asynchrony in intensive care unit: a translational observational study in China. BMC Med Educ. 2025 Feb 4;25(1):182. doi: 10.1186/s12909-025-06638-5. PubMed 39905371 ↗
  • Chen X, Yuan S, Kassis EB, Zhang S, Chi Y, Liu S, Cai F, Ma Y, Li Y, Su L, Long Y. Methodological development of the remote ventilate view platform for real-time monitoring of patient-ventilator asynchrony and respiratory parameters in severe pneumonia patients. J Intensive Med. 2025 Sep 23;5(4):367-376. doi: 10.1016/j.jointm.2025.07.003. eCollection 2025 Oct. PubMed 41180101 ↗
  • Chen X, Fan J, Zhao W, Shi R, Guo N, Chang Z, Song M, Wang X, Chen Y, Li T, Li GG, Su L, Long Y; on bahalf of Beijing Dongcheng Critical Care Quality Control Centre Group. Application of a cloud platform that identifies patient-ventilator asynchrony and enables continuous monitoring of mechanical ventilation in intensive care unit. Heliyon. 2024 Jun 27;10(13):e33692. doi: 10.1016/j.heliyon.2024.e33692. eCollection 2024 Jul 15. PubMed 39055813 ↗
  • Su L, Lan Y, Chi Y, Cai F, Bai Z, Liu X, Huang X, Zhang S, Long Y. Establishment and Application of a Patient-Ventilator Asynchrony Remote Network Platform for ICU Mechanical Ventilation: A Retrospective Study. J Clin Med. 2023 Feb 16;12(4):1570. doi: 10.3390/jcm12041570. PubMed 36836113 ↗
  • Su L, Yang Y, Wang Y, Lan J, Yue C, Yang M, Pensier J, Zhang S, Yang J, Zhang J, Shao H, Wang Y, Zhao J, Song X, Cao H, Wu H, Cai F, Ma Y, Song Z, Talmor D, Baedorf-Kassis E, Long Y. Real-time algorithm-driven ventilation feedback to improve lung-protective ventilation in patients with ARDS (REALVENT-study): study protocol for a multicentre randomised controlled trial. Respir Res. 2026 Jul 4. doi: 10.1186/s12931-026-03766-4. Online ahead of print. PubMed 42401979 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the primary and secondary outcome results (including the final trial dataset and data dictionary) may be shared with qualified investigators for methodologically sound proposals, after publication of the main results and subject to institutional and ethical approvals. Data will be shared via secure data transfer agreements and will not contain any directly identifiable information.

Supporting information: Study protocol, Informed consent form

Time frame: Data will become available within one year of completion of the final follow up assessment, or within one year of primary manuscript publication, whichever comes first. Data will be available for 10 years.

Access criteria: Outside investigators who wish to use data will submit a formal request, including rationale, analysis plan, and local Institutional Review Board (IRB) determination. Sponsor will review and respond to all requests. All data sharing will be codified by the appropriate contract / data use agreement. Recipient researchers must promise in writing to never attempt to access identifiable health/medical information or to attempt to identify the subject(s) who provided the specimen/data. Any intent to use materials or data for commercial purposes must be clearly disclosed as part of the request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 51 non-industry interventional studies with no phase under Acute Lung Injury, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 12 months is below that.

Counting every sponsor, half of 52 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 29, 2025
StartActual
Dec 30, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Feb 28, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07307066
Collaborators
Beijing Hepingli Hospital, Beijing No.6 Hospital, Jinzhou Medical University, Henan Provincial People's Hospital, Binzhou Second People's Hospital, Chongqing General Hospital, Qujing Central Hospital of Yunnan Province, Shandong Provincial Hospital, Capital Medical University Affiliated Beijing Anzhen Hospital, Nanchong Center
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Dec 30, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Longxiang Su, Doctor
Contact
slx77@163.com
+86 15652797257

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion